Literature DB >> 19793067

Immune reconstitution inflammatory syndrome associated with Aspergillus terreus pulmonary infection in an autologous stem cell transplant recipient.

S Antinori1, M Corbellino, A Necchi, P Corradini, C Vismara, V Montefusco, A M Gianni.   

Abstract

We describe an autologous stem cell transplant recipient who developed immune reconstitution inflammatory syndrome (IRIS) associated with Aspergillus terreus invasive pulmonary infection after recovery from neutropenia. Clinical and radiological worsening of pulmonary invasive aspergillosis coincident with a robust decline of serum galactomannan values and rising neutrophil counts should be interpreted as IRIS and should not require changes to antifungal therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19793067     DOI: 10.1111/j.1399-3062.2009.00460.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  3 in total

1.  Immune Reconstitution Inflammatory Syndrome as a Posttransplantation Complication in Primary Immunodeficiency With Disseminated Mycobacterium avium.

Authors:  Maura Manion; Dimana Dimitrova; Luxin Pei; Juan Gea-Banacloche; Adrian Zelazny; Andrea Lisco; Christa Zerbe; Alexandra F Freeman; Steven M Holland; Christopher G Kanakry; Jennifer A Kanakry; Irini Sereti
Journal:  Clin Infect Dis       Date:  2020-02-03       Impact factor: 9.079

Review 2.  Immune reconstitution reactions in human immunodeficiency virus-negative patients: report of a case and review of the literature.

Authors:  Tiffany C Scharschmidt; Erin H Amerson; Oren S Rosenberg; Richard A Jacobs; Timothy H McCalmont; Kanade Shinkai
Journal:  JAMA Dermatol       Date:  2013-01       Impact factor: 10.282

3.  Detection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosis.

Authors:  Simon F Dufresne; Kausik Datta; Xinming Li; Ekaterina Dadachova; Janet F Staab; Thomas F Patterson; Marta Feldmesser; Kieren A Marr
Journal:  PLoS One       Date:  2012-08-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.